Loading...
Market
Will Ultragenyx Commercially Launch Gene Therapy by May 30, 2025?
4
Resolution / Starting Odds
Yes • 50%
No • 50%
Ultragenyx official announcements and financial reports
Story
Ultragenyx ($RARE) Gene Therapy for Rare Liver Ailment Succeeds in Late-Stage Trial
May 30, 2024, 08:51 PM
Ultragenyx's gene therapy for a rare liver ailment has succeeded in a late-stage trial. The therapy, which aims to treat a condition affecting the liver, has shown promising results, marking a significant milestone for the company. The news, reported on May 30, 2024, was covered by multiple sources, including Jason Mast for Stat News. Ultragenyx is listed under the ticker symbol $RARE.
View original story
Similar markets
Successful phase 3 trial by another company • 25%
New regulatory approval • 25%
Major partnership or acquisition • 25%
Another failed trial • 25%
Yes • 50%
No • 50%
Success • 33%
Partial Success • 33%
Failure • 33%
